Skip to main content

Table 1 Non parametric parameters of the three groups on anti-HCV treatment

From: Impact of different anti-HCV regimens on platelet count during treatment in Egyptian patients

 

SIM/SOF

SOF/RBV

Triple

p value

Count

%

Count

%

Count

%

Sex

       

 Male

26

45.6%

32

58.2%

38

67.9%

0.057

 Female

31

54.4%

23

41.8%

18

32.1%

Residency

       

 Urban

34

59.6%

42

76.4%

35

62.5%

0.138

 Rural

23

40.4%

13

23.6%

21

37.5%

History of previous ttt

       

 ttt naïve

54

94.7%

35

64.8%

42

75.0%

< 0.001

 ttt experienced

3

5.3%

19

35.2%

14

25.0%

Smoking

       

 Yes

6

10.5%

7

12.7%

11

19.6%

0.354

 No

51

89.5%

48

87.3%

45

80.4%

Comorbidities (diabetes and/or hypertension)

       

 Yes

21

36.8%

21

38.2%

18

32.1%

0.783

 No

36

63.2%

34

61.8%

38

67.9%

Liver by ultrasound

       

 Normal

0

0.0%

2

3.6%

8

14.3%

< 0.001

 Cirrhotic

31

54.4%

47

85.5%

25

44.6%

 Abnormal echopattern

26

45.6%

6

10.9%

23

41.1%

Spleen by ultrasound

       

 Enlarged

28

49.1%

41

74.5%

35

62.5%

0.021

 Average

29

50.9%

14

25.5%

21

37.5%

Ascites by ultrasound

       

 Yes

0

0.0%

1

1.8%

1

1.8%

0.549

 No

57

100.0%

54

98.2%

55

98.2%

Child score calculation

       

 A5

25

43.9%

26

47.3%

50

89.3%

< 0.001

 A6

32

56.1%

21

38.2%

4

7.1%

 B7

0

0.0%

7

12.7%

2

3.6%

 B8

0

0.0%

1

1.8%

0

0.0%

Stage of fibrosis

       

 F1

3

27.3%

1

4.0%

2

8.0%

0.003

 F2

1

9.1%

1

4.0%

0

0.0%

 F3

1

9.1%

4

16.0%

14

56.0%

 F4

6

54.5%

18

72.0%

9

36.0%

 F5

0

0.0%

1

4.0%

0

0.0%

Stage of necroinflammatory activity

       

 A1

1

50.0%

2

25.0%

4

33.3%

0.749

 A2

1

50.0%

4

50.0%

7

58.3%

 A3

0

0.0%

1

12.5%

0

0.0%

 A7

0

0.0%

0

0.0%

1

8.3%

 A10

0

0.0%

1

12.5%

0

0.0%

Week 4 HCV RNA by PCR

       

 Positive

3

5.3%

7

12.7%

2

3.6%

0.183

 Negative

54

94.7%

48

87.3%

54

96.4%

Week 12 HCV RNA by PCR

       

 Positive

2

3.6%

1

1.8%

0

0.0%

0.325

 Negative

53

96.4%

54

98.2%

56

100.0%

HCV antiviral dose modification

       

 No

57

100.0%

54

98.2%

51

91.1%

0.025

 Modified

0

0.0%

1

1.8%

5

8.9%